Umbrella Review Maps Mortality Rates for Prosthetic Joint Infections

Bioengineer.org reported that researchers mapped treatment outcomes and prognostic factors for periprosthetic joint infection, a serious complication occurring around hip or knee implants. The umbrella review was authored by Jiamin Lu, Kai Zhang, and Yongfa Xia, and it was published in BMC Musculoskeletal Disorders. [1]

According to Bioengineer.org, the study synthesized 53 systematic reviews and meta-analyses gathered from searches of the Cochrane Library, Embase, PubMed, and Web of Science up to April 20, 2026. The research followed PRISMA guidelines to assess quantitative outcomes after treatment. [1]

The findings revealed a pooled mortality rate of 11.0 percent following hip prosthetic joint infections and 13.3 percent following knee prosthetic joint infections, according to Bioengineer.org. However, the certainty of the evidence was noted as generally low. [1]

As HEROIC BREAKING NEWS reported earlier, previous research published in BMC Infectious Diseases evaluated clindamycin treatments administered between 2010 and 2022. That study showed a low-dose regimen of 300 mg three times daily achieved an 82 percent success rate over two years in treating prosthetic joint infections. [4]